Literature DB >> 28410976

Genome editing via delivery of Cas9 ribonucleoprotein.

Mark A DeWitt1, Jacob E Corn2, Dana Carroll3.   

Abstract

The CRISPR-Cas genome editing system is very powerful. The format of the CRISPR reagents and the means of delivery are often important factors in targeting efficiency. Delivery of recombinant Cas9 protein and guide RNA (gRNA) as a preformed ribonucleoprotein (RNP) complex has recently emerged as a powerful and general approach to genome editing. Here we outline methods to produce and deliver Cas9 RNPs. A donor DNA carrying desired sequence changes can also be included to program precise sequence introduction or replacement. RNP delivery limits exposure to genome editing reagents, reduces off-target events, drives high rates of homology-dependent repair, and can be applied to embryos to rapidly generate animal models. RNP delivery thus minimizes some of the pitfalls of alternative editing modalities and is rapidly being adopted by the genome editing community.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28410976      PMCID: PMC6698184          DOI: 10.1016/j.ymeth.2017.04.003

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  46 in total

1.  Spatiotemporal Control of CRISPR/Cas9 Function in Cells and Zebrafish using Light-Activated Guide RNA.

Authors:  Wenyuan Zhou; Wes Brown; Anirban Bardhan; Michael Delaney; Amber S Ilk; Randy R Rauen; Shoeb I Kahn; Michael Tsang; Alexander Deiters
Journal:  Angew Chem Int Ed Engl       Date:  2020-04-06       Impact factor: 15.336

Review 2.  Applying gene editing to tailor precise genetic modifications in plants.

Authors:  Joyce Van Eck
Journal:  J Biol Chem       Date:  2020-07-28       Impact factor: 5.157

Review 3.  Technical considerations for the use of CRISPR/Cas9 in hematology research.

Authors:  Michael C Gundry; Daniel P Dever; David Yudovich; Daniel E Bauer; Simon Haas; Adam C Wilkinson; Sofie Singbrant
Journal:  Exp Hematol       Date:  2017-07-27       Impact factor: 3.084

4.  Genome editing technologies and their potential to treat neurologic disease.

Authors:  Nicolas N Madigan; Nathan P Staff; Anthony J Windebank; Eduardo E Benarroch
Journal:  Neurology       Date:  2017-09-20       Impact factor: 9.910

Review 5.  CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.

Authors:  Rimsha Farooq; Khadim Hussain; Muhammad Tariq; Ali Farooq; Muhammad Mustafa
Journal:  J Appl Genet       Date:  2020-01-07       Impact factor: 3.240

6.  Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.

Authors:  Meisam Naeimi Kararoudi; Hamid Dolatshad; Prashant Trikha; Syed-Rehan A Hussain; Ezgi Elmas; Jennifer A Foltz; Jena E Moseman; Aarohi Thakkar; Robin J Nakkula; Margaret Lamb; Nitin Chakravarti; K John McLaughlin; Dean A Lee
Journal:  J Vis Exp       Date:  2018-06-14       Impact factor: 1.355

7.  A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver.

Authors:  Jing Gong; Hong-Xia Wang; Yeh-Hsing Lao; Hanze Hu; Naazanene Vatan; Jonathan Guo; Tzu-Chieh Ho; Dantong Huang; Mingqiang Li; Dan Shao; Kam W Leong
Journal:  Adv Mater       Date:  2020-10-14       Impact factor: 30.849

8.  Efficient mouse genome engineering by CRISPR-EZ technology.

Authors:  Andrew J Modzelewski; Sean Chen; Brandon J Willis; K C Kent Lloyd; Joshua A Wood; Lin He
Journal:  Nat Protoc       Date:  2018-05-10       Impact factor: 13.491

9.  Lipofection-mediated genome editing using DNA-free delivery of the Cas9/gRNA ribonucleoprotein into plant cells.

Authors:  Wusheng Liu; Mary R Rudis; Matthew H Cheplick; Reginald J Millwood; Jian-Ping Yang; Christine A Ondzighi-Assoume; Garrett A Montgomery; Kellie P Burris; Mitra Mazarei; Jonathan D Chesnut; Charles Neal Stewart
Journal:  Plant Cell Rep       Date:  2019-11-14       Impact factor: 4.570

Review 10.  CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.

Authors:  Hanan Bloomer; Jennifer Khirallah; Yamin Li; Qiaobing Xu
Journal:  Adv Drug Deliv Rev       Date:  2021-12-20       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.